» Articles » PMID: 15316202

Interstitial Lung Disease Induced by Drugs and Radiation

Overview
Journal Respiration
Publisher Karger
Specialty Pulmonary Medicine
Date 2004 Aug 19
PMID 15316202
Citations 118
Authors
Affiliations
Soon will be listed here.
Abstract

An ever-increasing number of drugs can reproduce variegated patterns of naturally occurring interstitial lung disease (ILD), including most forms of interstitial pneumonias, alveolar involvement and, rarely, vasculitis. Drugs in one therapeutic class may collectively produce the same pattern of involvement. A few drugs can produce more than one pattern of ILD. The diagnosis of drug-induced ILD (DI-ILD) essentially rests on the temporal association between exposure to the drug and the development of pulmonary infiltrates. The histopathological features of DI-ILD are generally consistent, rather than suggestive or specific to the drug etiology. Thus, the diagnosis of DI-ILD is mainly made by the meticulous exclusion of all other possible causes. Drug dechallenge produces measurable improvement in symptoms and imaging in the majority of patients, whereas corticosteroid therapy is indicated if symptoms are present or drug dechallenge is without an effect. Rechallenge is justified in a minority of patients, and is discouraged for diagnostic purposes only. Pneumotox (www.pneumotox.com) provides updated information on drug-induced respiratory disease.

Citing Articles

The Between Lung Cancer and Interstitial Lung Diseases: A Focus on Acute Exacerbation.

Zanini U, Faverio P, Bonfanti V, Falzone M, Cortinovis D, Arcangeli S J Clin Med. 2024; 13(23).

PMID: 39685543 PMC: 11641964. DOI: 10.3390/jcm13237085.


A case report of interstitial lung disease caused by HER2-positive breast cancer patient receiving two antibody-drug conjugate drugs successively.

Xie W, Wang T, Wang X Transl Breast Cancer Res. 2024; 5:36.

PMID: 39534578 PMC: 11557153. DOI: 10.21037/tbcr-24-19.


Diagnosis and Management of Drug-Induced Interstitial Lung Disease in the context of Anti-Cancer Therapy: a Multidisciplinary Viewpoint by Portuguese Experts.

Fontes E Sousa M, Campainha S, Marques I, Dinis R, Inacio J, Mendes J Clin Drug Investig. 2024; 44(11):801-810.

PMID: 39500817 PMC: 11564330. DOI: 10.1007/s40261-024-01400-z.


Drug-induced lung disease: a narrative review.

Bridi G, Fonseca E, Kairalla R, Amaral A, Baldi B J Bras Pneumol. 2024; 50(4):e20240110.

PMID: 39356911 PMC: 11449616. DOI: 10.36416/1806-3756/e20240110.


Updates in Dermatomyositis: Newer Treatment Options and Outcome Measures From Dermatologic Perspectives.

Kim H, Werth V Ann Dermatol. 2024; 36(5):257-265.

PMID: 39343752 PMC: 11439981. DOI: 10.5021/ad.24.022.